Q3 2023 EPS Estimates for Krystal Biotech, Inc. Lifted by Analyst (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Research analysts at William Blair upped their Q3 2023 earnings per share (EPS) estimates for Krystal Biotech in a note issued to investors on Monday, May 22nd. William Blair analyst T. Lugo now expects that the company will earn ($1.25) per share for the quarter, up from their prior estimate of ($1.26). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.69) per share. William Blair also issued estimates for Krystal Biotech’s Q4 2023 earnings at ($0.89) EPS, FY2023 earnings at ($5.20) EPS, Q1 2024 earnings at ($0.78) EPS, Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.30 EPS, FY2024 earnings at ($0.86) EPS, FY2025 earnings at $2.44 EPS and FY2026 earnings at $4.21 EPS.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.01.

Several other research analysts have also issued reports on KRYS. Bank of America increased their price objective on Krystal Biotech from $105.00 to $118.00 in a research note on Sunday, May 21st. The Goldman Sachs Group upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and increased their target price for the stock from $79.00 to $124.00 in a report on Tuesday, February 28th. Chardan Capital increased their target price on Krystal Biotech from $133.00 to $148.00 in a report on Monday. HC Wainwright increased their target price on Krystal Biotech from $119.00 to $139.00 in a report on Monday. Finally, Guggenheim increased their target price on Krystal Biotech from $101.00 to $130.00 in a report on Monday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $134.00.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $117.39 on Wednesday. The stock has a fifty day moving average price of $86.67 and a two-hundred day moving average price of $81.02. Krystal Biotech has a 52-week low of $49.17 and a 52-week high of $123.84. The firm has a market capitalization of $3.03 billion, a P/E ratio of -22.23 and a beta of 0.85.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $109.04, for a total value of $2,726,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,369,106.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CAO Kathryn Romano sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $109.04, for a total value of $2,726,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,369,106.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dino A. Rossi sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total value of $3,330,000.00. Following the completion of the transaction, the director now owns 83,691 shares in the company, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Insiders have sold a total of 193,428 shares of company stock worth $17,965,513 over the last 90 days. Insiders own 17.00% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Almanack Investment Partners LLC. bought a new position in Krystal Biotech during the third quarter worth about $52,000. Allspring Global Investments Holdings LLC boosted its holdings in Krystal Biotech by 260.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 981 shares of the company’s stock worth $68,000 after buying an additional 709 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Krystal Biotech by 51.9% during the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock worth $72,000 after buying an additional 346 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Krystal Biotech by 148.3% during the first quarter. Tower Research Capital LLC TRC now owns 956 shares of the company’s stock worth $77,000 after buying an additional 571 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Krystal Biotech during the first quarter worth about $104,000. Institutional investors own 80.80% of the company’s stock.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.